UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of AZD0530, a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung (10)

The participants in this study have been diagnosed with recurrent osteosarcoma in the lung and have received standard treatments for this type of cancer. The purpose of this research study is to see if participants will benefit from taking a drug called AZD0530. Approximately 5 people will take part in this study conducted by researchers at the University of Iowa. Study involvement will last for approximately 5 years.

Start Date
November 29, 2009
End Date
November 29, 2019
Gender Preference
Age Group
0 - 99 years
Principal Investigator
Mohammed Milhem, MD
Contact Info

Cindy Robertson, 319-356-2778

AZD0530 ; cancer ; IRB#200903799 ; lung ; milhem ; osteosarcoma ; pediatric ; phase 2 ; phase II ; SARC012 ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.